Profile of fungal septicaemia in new born at a tertiary care hospital in North India


  • Neerul Pandita Department of Pediatrics, Himaliyan Hospital, Doiwala, Dehradun, Uttarakhand, India
  • Chetan Peshin Department of Pediatrics, Himaliyan Hospital, Doiwala, Dehradun, Uttarakhand, India
  • Sanobar Wasim Department of Pediatrics, Himaliyan Hospital, Doiwala, Dehradun, Uttarakhand, India
  • Nowneet Kumar Bhat Department of Pediatrics, Himaliyan Hospital, Doiwala, Dehradun, Uttarakhand, India
  • Alpa Gupta Department of Pediatrics, Himaliyan Hospital, Doiwala, Dehradun, Uttarakhand, India



Candida, Fungal sepsis, Fungal blood stream infection, Neonates


Background: Advances in neonatal management have led to considerable improvement in new-born survival. The objective of this study was to determine the predominant organisms, antifungal sensitivity patterns and clinical risk factors in neonatal fungal blood stream infection cases (BSI) admitted to our hospital.

Methods: This is a retrospective study of all neonatal fungal BSI cases between January 2015 to December 2015.

Results: Fungal sepsis was found in 50/360 (13.6%) of cases. Non Albicans candida (NAC)species were responsible for 88% of cases with Candida. glabrata (54%)as the most predominant species. Other species isolated were C. tropicalis 9 (18%). C. albicans 6 (12%). C. paraspinolosis 5 (10%), C. Krusei 2 (4%) and C. Kodo1 (2%). Antifungal sensitivity results revealed that most of the NAC isolates especially candida glabrata,candida paraspinolosis were resistant to flucanazole, than Candida albicans. Amphoterician B had greater sensitivity than FLK over NAC species Among the risk factor observed for candidemia were low birth weight (62%), prematurity (60%,), broad spectrum antibiotic use (60%), ventilater support (56%) and total parentral nutrition (50%).

Conclusions: The increase in neonatal fungal BSI and resistant organisms highlights the need to review use of strict infection control strategies, appropriate preventive and therapeutic measures such as prophylactic antifungal use and a restrictive policy of antibiotic use. 


Benjamin DK, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatr. 2006;117(1):84-92.

Baley JE. Neonatal candidiasis: the current challenge. Clin Perinatol. 1991;18(2):263-80.

Goel N, Ranjan PK, Aggarwal R, Chaudhary U, Sanjeev N. Emergence of non albicans Candida in neonatal septicemia and antifungal susceptibility: Experience from a reference tertiary care center. J Lab Physicians. 2009;1(2):53-5.

Oberoi JK, Wattal C, Goel N, Raveendran R, Datta S, Prasad K. Non-albicans Candida species in blood stream infections in a tertiary care hospital at New Delhi, India. Indian J Med Res. 2012;136(6):997-1003.

Magill SS, Shields C, Sears CL, Choti M, Merz WG. Triazole cross-resistance among Candida spp.: Case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol. 2006;44:529-35.

Huang YC, Li CC, Liu TY, Lien RI, Chou YH, Wu JL, et al. Association of fungal colonization and invasive disease in very low birth weight infants. Paediatr Infect Dis J. 1992;17:819-22.

Robertson NR. Neonatal infections. In Robertson Textbook of Neonatology, 2nd edn. Churchill Living Stone; 1992:984-5.

Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very ;low birth weight infants: clinical manifestations and epidemiology. Pediatr. 1992;73:144-52.

Libovitz E. Neonatal candidiasis: clinical picture, management controversies and consensus and new therapeutic options. J Antimicrobial Chemother. 2002;49:69-73.

Singhi S, Rao DS, Chakrabarti A. Candida colonization and candidemia in a pediatric intensive care unit. Pediatr Crit Care Med. 2008;9:91-5.

Ariff S, Saleem AF, Soofi SB, Sajjad R. Clinical spectrum and outcomes of neonatal candidiasis in a tertiary care hospital in Karachi, Pakistan. J Infect Dev Ctries. 2011;5:216-23.

Zaoutis TE, Prasad PA, Localio AR, Coffin SE, Bell LM, Walsh TJ, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: Implications for prevention. Clin Infect Dis. 2010;51:38-45.

Benjamin DK, Ross K, McKinney RE, Benjamin DK, Auten R. When to suspect fungal infection in neonates: a clinical comparision of candida albicans and candida paraspilosis fungemia with coagulase -negative staphylococcal bacterimia. Paediatr. 2000:106:712-8.

Kler N, Garg P. Fungal sepsis. Bull Nat Neonatol Forum. 1999;13:13-5.

Davis LE. Fungal infections of the central nervous system. Neurol Clin. 1999;17:761.

Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37:1172-7.

McGinnis MR. Laboratory Handbook of Medical Mycology. New York: Academic Press. Yeast Identification; 1980:337-73.

Barry AL, Brown SD. Fluconazole disk diffusion procedure for determining susceptibility of Candidaspecies. J Clin Microbiol. 1996;34:2154-7.

Kirkpatrick WR, Turner TM, Fothergill AW, McCarthy DI, Redding SW, Rinaldi MG, et al. Fluconazole disk diffusion susceptibility testing of Candida species. J Clin Microbiol. 1998;36:3429-32.

Pennysylvania, USA. Clinical Laborotory and Standards Institutes. Performance standards for antimicrobial suseptibility testings; twenty first informational supplement; 2011:100-S21.

Agarwal J, Bansal S, Malik GK, Jain A. Trends in neonatal septicemia: Emergence of non-albicans Candida. Indian Pediatr. 2004;41:712-5.

Rani R, Mohapatra NP, Mehta G, Randhawa VS. Changing trends of Candida species in neonatal septicemia in a tertiary north Indian hospital. Indian J Med Microbiol. 2002;20:42-4.

Sardana V, Pandey A, Madan M, Goel SP, Asthana AK. Neonatal candidemia: a changing trend. Indian J Pathol Microbiol. 2012;55:132-3.

Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: Trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J. 1998;17:504-8.

Karen DF, Smita T, Erica S, Fernando MV. Neonatal Candida glabrata sepsis: Clinical and laboratory features compared with other Candida species. Pediatr Infect Dis J. 2002;22:39-43.

Paul LF, Vanquez JA, Sobel JD. Candida glabrata: Review of epidemiology, pathogenesis and clinical disease with comparison to C. albicans. Clin Microbiol Rev. 1999;12:80-96.

Rinaldi M, Marr KA. Clinical significance of azole antifungal drug cross resistance in Canduda glabrata. J Clin Microbiol. 2006;44:1740-3.

Roilides E, Farmaki E, Evdoridou J, Francesconi A, Kasai M, Filioti J, et al. Candida tropicalis in a neonatal intensive care unit: Epidemiologic and molecular analysis of an outbreak of infection with an uncommon neonatal pathogen. J Clin Microbiol. 2003;41:735-41.

Sobel JD, Zervos M, Reed BD, Hooton T, Soper D, Nyirjesy P, et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: Clinical implications. Antimicrob Agents Chemother. 2003;47:34-8.

Tseng Y, Lee W, Kuo T. In-Vitro susceptibility of fluconazole and amphotericin B against Candidaisolates from women with Vaginal Candidiasis in Taiwan. J Food Drug Anal. 2005;13:12-6.






Original Research Articles